Thermo Fisher Scientific Inc. (NYSE:TMO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Thermo Fisher Scientific Inc. (NYSE:TMO) has been assigned a consensus rating of “Moderate Buy” from the twenty-five brokerages that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $602.1364.

A number of analysts have recently commented on the company. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Piper Sandler began coverage on Thermo Fisher Scientific in a research note on Thursday, June 11th. They set a “neutral” rating and a $510.00 price target for the company. Wolfe Research assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective on the stock. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th.

Thermo Fisher Scientific Trading Up 0.4%

Shares of TMO stock traded up $2.01 during trading hours on Monday, hitting $526.72. 1,233,008 shares of the company were exchanged, compared to its average volume of 1,993,707. The firm has a fifty day moving average of $478.23 and a 200 day moving average of $516.44. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific has a 1 year low of $403.36 and a 1 year high of $643.99. The firm has a market cap of $195.74 billion, a PE ratio of 28.96, a PEG ratio of 2.32 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Analysts expect that Thermo Fisher Scientific will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Large investors have recently modified their holdings of the stock. Legacy Wealth Managment LLC ID grew its position in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares in the last quarter. Allied Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth $26,000. High Note Wealth LLC boosted its stake in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares during the period. Swiss RE Ltd. acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $28,000. Finally, JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific in the 3rd quarter worth $28,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.